89 related articles for article (PubMed ID: 2421893)
1. Pharmacologic analysis of the ip administration of fludarabine phosphate in the swine.
Weiss GR; Gaskill HV; Phillips JL
Cancer Treat Rep; 1986 Apr; 70(4):499-502. PubMed ID: 2421893
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
Malspeis L; Grever MR; Staubus AE; Young D
Semin Oncol; 1990 Oct; 17(5 Suppl 8):18-32. PubMed ID: 1699279
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study of fludarabine phosphate (NSC 312887).
Hersh MR; Kuhn JG; Phillips JL; Clark G; Ludden TM; Von Hoff DD
Cancer Chemother Pharmacol; 1986; 17(3):277-80. PubMed ID: 2427240
[TBL] [Abstract][Full Text] [Related]
4. Encapsulation, metabolism and release of 2-fluoro-ara-AMP from human erythrocytes.
Fraternale A; Rossi L; Magnani M
Biochim Biophys Acta; 1996 Oct; 1291(2):149-54. PubMed ID: 8898876
[TBL] [Abstract][Full Text] [Related]
5. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
[TBL] [Abstract][Full Text] [Related]
6. 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.
Danhauser L; Plunkett W; Keating M; Cabanillas F
Cancer Chemother Pharmacol; 1986; 18(2):145-52. PubMed ID: 2431803
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine monophosphate for prolymphocytic leukaemia.
Smith OP; Mehta AB
Lancet; 1990 Sep; 336(8718):820. PubMed ID: 1698237
[No Abstract] [Full Text] [Related]
8. Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences.
Gandhi V; Huang P; Chapman AJ; Chen F; Plunkett W
Clin Cancer Res; 1997 Aug; 3(8):1347-55. PubMed ID: 9815818
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous-infusion schedule.
Leiby JM; Grever MR; Staubus AE; Neidhart JA; Malspeis L
J Natl Cancer Inst; 1988 May; 80(6):447-9. PubMed ID: 2452888
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of fludarabine (2-fluoro-ara-AMP).
Kavanagh JJ; Krakoff IH; Bodey GP
Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1009-11. PubMed ID: 2415365
[TBL] [Abstract][Full Text] [Related]
11. Stability of vidarabine-5'-phosphate in aqueous solutions.
Hong WH; Szulczewski DH
J Parenter Sci Technol; 1984; 38(2):60-4. PubMed ID: 6202864
[No Abstract] [Full Text] [Related]
12. Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-phosphate in mice and dogs.
Noker PE; Duncan GF; El Dareer SM; Hill DL
Cancer Treat Rep; 1983 May; 67(5):445-56. PubMed ID: 6189605
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study.
Shevrin DH; Lad TE; Kilton LJ; Cobleigh MA; Blough RR; Weidner LL; Vogelzang NJ
Invest New Drugs; 1989 Jul; 7(2-3):251-3. PubMed ID: 2477345
[TBL] [Abstract][Full Text] [Related]
14. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model.
Pestieau SR; Stuart OA; Sugarbaker PH
Eur J Surg Oncol; 2000 Nov; 26(7):696-700. PubMed ID: 11078617
[TBL] [Abstract][Full Text] [Related]
15. High-pressure liquid chromatographic methods for determining arabinosyladenine-5'-monophosphate, arabinosyladenine, and arabinosylhypoxanthine in plasma and urine.
McCann WP; Hall LM; Siler W; Barton N; Whitley RJ
Antimicrob Agents Chemother; 1985 Aug; 28(2):265-73. PubMed ID: 2423028
[TBL] [Abstract][Full Text] [Related]
16. Determination of fludarabine phosphate in human plasma using reversed phase high-performance liquid chromatography.
Misztal G; Paw B
Pharmazie; 1996 Oct; 51(10):733-4. PubMed ID: 8941940
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate.
Yin W; Karyagina EV; Lundberg AS; Greenblatt DJ; Lister-James J
Biopharm Drug Dispos; 2010 Jan; 31(1):72-81. PubMed ID: 19862681
[TBL] [Abstract][Full Text] [Related]
18. The potentiation of radiation response on murine tumor by fludarabine phosphate.
Kim JH; Alfieri AA; Kim SH; Fuks Z
Cancer Lett; 1986 Apr; 31(1):69-76. PubMed ID: 2421870
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic activity of 2-Fluoro-ara-AMP and 2-Fluoro-ara-AMP-loaded erythrocytes against human breast carcinoma cell lines.
Pierigè F; De Marco C; Orlotti N; Dominici S; Biagiotti S; Serafini S; Zaffaroni N; Magnani M; Rossi L
Int J Oncol; 2010 Jul; 37(1):133-42. PubMed ID: 20514405
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
